Some have reported that CDK4/6 inhibitors strengthen cancer cell immunogenicity, promote an immunomodulatory senescence-associated secretory phenotype (SASP), and induce T effector cell infiltration and activation28,45–47,49,50. This evidence concerns the gene CDK4 and cancer.